Xiaodong Wang Purchases 99,892 Shares of ONC

Xiaodong Wang made a significant move by purchasing 99,892 shares of ONC on June 11, 2026. This insider buy did not involve any cash payment, as the transaction price was recorded at $0.0 per share. ONC shares were trading at $264.48 at the time.

Other Institutional Activity in ONC

Several institutional investors have been active in ONC. Baker Bros. Advisors LP maintained its position with 8,799,053 shares valued at $2.61 billion. Primecap Management Co/CA/ slightly reduced its stake by 5,400 shares, bringing its total to 4,975,181 shares worth about $1.48 billion. Capital International Investors cut its holdings by 955,140 shares, now holding 4,158,726 shares valued at $1.23 billion. FMR LLC also decreased its position, selling 299,017 shares to hold 3,693,610 shares valued at $1.1 billion. Meanwhile, Capital World Investors added 1,622,687 shares, bringing their total to the same number, valued at $481.9 million.

BeOne Medicines AG Stock Down 27.9%

Shares of ONC are currently trading at $264.48. The company has been receiving attention with a range of analyst price targets, reflecting varying levels of optimism about its future performance.

Insider Buying and Selling at BeOne Medicines AG

On June 11, 2026, multiple insiders, including Xiaodong Wang, engaged in significant stock purchases. Wang acquired a total of 193,492 shares, while Shalini Sharp and Charles Lazelle Sawyers each bought 18,980 shares. Lee Chan Henry, SVP and General Counsel, purchased 45,071 shares. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

Analysts have been actively updating their views on ONC. RBC Capital maintained its 'buy' rating with a price target of $436 on June 2, 2026. Earlier, on May 15, 2026, Leerink Partners also maintained a 'buy' rating, setting a target of $367. Guggenheim and Barclays both reiterated 'buy' ratings with targets of $420 and $409, respectively, on May 7, 2026. Truist Securities echoed this sentiment with a $413 target. Wells Fargo initiated coverage with a 'buy' rating and a $400 target on May 4, 2026. Wolfe Research initiated at $340, while Jefferies downgraded the stock to 'hold' with a $290 target on March 16, 2026.

Bottom Line

Xiaodong Wang's purchase of ONC shares signals confidence in the company's prospects. Investors watch insider transactions closely, as they can provide insights into a company's future. It's important to remember that these insider purchases are based on past data and do not necessarily reflect current market conditions.